Shedding and transmission of novel influenza virus A/H1N1 infection in households--Germany, 2009.

Essential epidemiologic and virologic parameters must be measured to provide evidence for policy/public health recommendations and mathematical modeling concerning novel influenza A/H1N1 virus (NIV) infections. Therefore, from April through August of 2009, the authors collected nasopharyngeal specimens and information on antiviral medication and symptoms from households with NIV infection on a daily basis in Germany. Specimens were analyzed quantitatively by using reverse transcriptase-polymerase chain reaction. In 36 households with 83 household contacts, 15 household contacts became laboratory-confirmed secondary cases of NIV. Among 47 contacts without antiviral prophylaxis, 12 became cases (secondary attack rate of 26%), and 1 (8%) of these was asymptomatic. The mean and median serial interval were 2.6 and 3 days, respectively (range: 1-3 days). On average, the authors detected viral RNA copies for 6.6 illness days (treated in time = 5.7 days, not treated in time = 7.1 days; P = 0.06), but they estimated that most patients cease to excrete viable virus by the fifth illness day. Shedding profiles were consistent with the number and severity of symptoms. Compared with other nasopharyngeal specimen types, nasal wash was the most sensitive. These results support the notion that epidemiologic and virologic characteristics of NIV are in many aspects similar to those of seasonal influenza.

[1]  L. Finelli,et al.  Emergence of a novel swine-origin influenza A (H1N1) virus in humans. , 2009, The New England journal of medicine.

[2]  L. Huson,et al.  Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. , 1999, The New England journal of medicine.

[3]  A. Monto,et al.  Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households. , 2002, The Journal of infectious diseases.

[4]  J. Oxford,et al.  Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. , 2001, JAMA.

[5]  D M Fleming,et al.  Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. , 1997, The New England journal of medicine.

[6]  H. Goldstein Multilevel Statistical Models , 2006 .

[7]  B. Cowling,et al.  Estimation of the Serial Interval of Influenza , 2009, Epidemiology.

[8]  Fabrice Carrat,et al.  INFLUENZA BURDEN OF ILLNESS: ESTIMATES FROM A NATIONAL PROSPECTIVE SURVEY OF HOUSEHOLD CONTACTS IN FRANCE , 2002, Archives of internal medicine.

[9]  Pan Xin,et al.  Novel Swine-Origin Influenza A(H1N1) Virus , 2009 .

[10]  H. Jackson,et al.  Oral Oseltamivir in Human Experimental Influenza B Infection , 1999, Antiviral therapy.

[11]  K. Taniguchi,et al.  Assessment of secondary attack rate and effectiveness of antiviral prophylaxis among household contacts in an influenza A(H1N1)v outbreak in Kobe, Japan, May-June 2009. , 2009, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[12]  Cécile Viboud,et al.  Risk factors of influenza transmission in households. , 2004, The British journal of general practice : the journal of the Royal College of General Practitioners.

[13]  C. Carlson,et al.  Comparison of Four Clinical Specimen Types for Detection of Influenza A and B Viruses by Optical Immunoassay (FLU OIA Test) and Cell Culture Methods , 1999, Journal of Clinical Microbiology.

[14]  William Morris The American Heritage dictionary of the English language , 1969 .

[15]  Mark R. Duffy,et al.  Novel Influenza A (H1N1) outbreak at the U.S. Air Force Academy: epidemiology and viral shedding duration. , 2010, American journal of preventive medicine.

[16]  P. Ward,et al.  Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. , 1999, JAMA.

[17]  B. Cowling,et al.  Preliminary Findings of a Randomized Trial of Non-Pharmaceutical Interventions to Prevent Influenza Transmission in Households , 2008, PloS one.

[18]  H. Klenk,et al.  New low-viscosity overlay medium for viral plaque assays , 2006, Virology Journal.

[19]  N. Ferguson,et al.  Time lines of infection and disease in human influenza: a review of volunteer challenge studies. , 2008, American journal of epidemiology.

[20]  Rosalia M. Kalani,et al.  Introduction and transmission of 2009 pandemic influenza A (H1N1) Virus--Kenya, June-July 2009. , 2009, MMWR. Morbidity and mortality weekly report.

[21]  David Buckeridge,et al.  Estimated epidemiologic parameters and morbidity associated with pandemic H1N1 influenza , 2010, Canadian Medical Association Journal.

[22]  K. Carlsen,et al.  Comparison of four nasal sampling methods for the detection of viral pathogens by RT-PCR—A GA2LEN project☆ , 2008, Journal of Virological Methods.

[23]  J. Peiris,et al.  Viral load in patients infected with pandemic H1N1 2009 influenza A virus , 2009, Journal of medical virology.

[24]  Leming,et al.  Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections , 1997 .

[25]  Bin Cao,et al.  Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China. , 2009, The New England journal of medicine.

[26]  C. Fraser,et al.  Household transmission of 2009 pandemic influenza A (H1N1) virus in the United States. , 2009, The New England journal of medicine.

[27]  C. Viboud,et al.  A Bayesian MCMC approach to study transmission of influenza: application to household longitudinal data , 2004, Statistics in medicine.

[28]  Simon Cauchemez,et al.  The Early Transmission Dynamics of H1N1pdm Influenza in the United Kingdom , 2010, PLoS currents.

[29]  林明輝,et al.  World Health Organization 2009精蟲分析新標準 , 2012 .

[30]  H. Klenk,et al.  Overexpression of the α-2,6-Sialyltransferase in MDCK Cells Increases Influenza Virus Sensitivity to Neuraminidase Inhibitors , 2003, Journal of Virology.

[31]  E. Lyons,et al.  Pandemic Potential of a Strain of Influenza A (H1N1): Early Findings , 2009, Science.

[32]  D. Cummings,et al.  Strategies for containing an emerging influenza pandemic in Southeast Asia , 2005, Nature.